Asunto(s)
Femenino , Humanos , Enfermedades Urogenitales Femeninas , Ginecología , Menopausia , Obstetricia , Aborto , Anticoncepción , Embarazo Ectópico , ReproducciónRESUMEN
Contenido: Anatomía del aparato genital femenino y de la glándula mamaria. Embriología urogenital y mamaria. Fisiología genital femenina. Etapas evolutivas biológicas de la mujer y de la personalidad femenina. Semiología ginecológica. Alteraciones del ciclo sexual bifásico. Anovulación crónica. Metrorragias. Infecciones ginecológicas. Enfermedad pelviana inflamatoria. Aborto. Embarazo ectópico. Enfermedad trofoblástica gestacional. Tumores del ovario. Patología cervical uterina. Patología vaginal. Patología vulvar. Endometrosis. Anomalías del desarrollo. Distopias genitales. Patología urinaria de la mujer. Reproducción humana. Planificación familiar. Hormonoterapia. Biología tumoral. Operaciones ginecológicas. Patología mamaria. Dolor en ginecología...
Asunto(s)
Humanos , GinecologíaRESUMEN
OBJECTIVE AND DESIGN: Gross cystic disease (GCD) of the breast is reported to occur in 7% of women in the developed world and, although not premalignant, is thought to be associated with an increased risk of breast cancer. Hormone and growth factor concentration levels were measured in breast cyst fluid (BCF) to correlate them with their mitogenic activity in tumour (MCF-7) or nontransformed (MCF-10A) cells. RESULTS: Oestradiol (E2), oestrone (E1), E2-sulfate (E2-S), E1-sulfate (E1-S) and epidermal growth factor (EGF) concentrations were, as expected, significantly higher in type I than in type II cysts, while transforming growth factor-beta 2 (TGF-beta2) showed higher levels in type II cysts. Fifty per cent of the BCF samples stimulated [3H]-thymidine incorporation into MCF-7 cells while 34.5% inhibited this parameter. In MCF-10A cells, most BCF samples were stimulatory (85%). E2, E1 and EGF concentrations in BCF samples correlated significantly and positively with cell proliferation in MCF-7 cells, whereas a significant negative correlation was found for TGF-beta2. In MCF-10A cells, only E2-S and E1-S exhibited significant positive correlation, whereas a significant negative correlation was found for TGF-beta2. Progesterone (Pg), E2 and EGF incubated under the same conditions had a stimulatory effect on [3H]-thymidine incorporation into MCF-7 cells, whereas TGF-beta2 inhibited this parameter. Pg, E2, E1 and EGF significantly stimulated this parameter in MCF-10A cells. CONCLUSIONS: The stimulatory action of BCF on cell proliferation in a model of human breast epithelial cells could partly explain the increased incidence of breast cancer in cyst-bearing women.
Asunto(s)
Quiste Mamario/metabolismo , Línea Celular Tumoral/patología , Hormona del Crecimiento/metabolismo , Hormonas/metabolismo , Adulto , Líquidos Corporales/química , Líquidos Corporales/metabolismo , Línea Celular Tumoral/metabolismo , Proliferación Celular , Factor de Crecimiento Epidérmico/análisis , Células Epiteliales/patología , Femenino , Humanos , Concentración de Iones de Hidrógeno , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/análisis , Factor I del Crecimiento Similar a la Insulina/análisis , Potasio/análisis , Sodio/análisis , Factor de Crecimiento Transformador beta/análisisRESUMEN
OBJECTIVE: There are no randomized studies of the two therapeutic alternatives (surgery or radiotherapy) for occult cervical carcinoma, and survival rates in the absence of residual cancer seem to be similar for both. This article presents our experience with radical reoperation for occult cervical carcinoma. MATERIALS AND METHODS: Eleven patients with occult cervical cancer, primary invasive tumor >/=0.5 cm and =3.0 cm, free margins in the hysterectomy specimen, and absence of clinically evident residual tumor were reoperated (radical parametrectomy with partial colpectomy and pelvic lymphadenectomy). RESULTS: Histopathologic examination after reoperation showed no evidence of residual disease in nine cases and metastasis in lymph nodes in two cases, one of them with parametrial involvement. Survival was 100% among disease-free cases on reoperation and 0% in cases with residual disease (5-year follow-up). CONCLUSIONS: Radical reoperation allows disease staging, sorting of patients into risk groups, and avoidance of radiation therapy in more than two thirds of the cases of occult cervical carcinoma.
RESUMEN
Tumor MUC1 expression as well as levels of MUC1, MUC1 circulating immune complexes (MUC1-CIC) and free antibodies against MUC1 (IgG and IgM-MUC1) were evaluated in 70 breast cancer patients with different stages of disease. Controls included: 135 serum samples from healthy women, normal mammary tissue samples (n = 7) and benign breast disease specimens (n = 6). In all assays, pre- and post-vaccination serum samples from breast cancer patients belonging to a vaccination protocol developed at the Memorial Sloan Kettering Cancer Center (New York, USA) were included as controls. Serum MUC1 was measured through Cancer Associated Serum Antigen test and CA15-3 test. Employing ELISA, MUC1-CIC-IgG/M were measured with either C595 or SM3 monoclonal antibodies (MAb) as catchers and also free antibodies against MUC1 (IgG and IgM) using 100mer peptide as catcher. Employing multivariate statistical analysis, results were correlated with age, tumor type, stage of disease and grade of differentiation. By quantitative immunohistochemistry using three anti-MUC1 core protein MAbs (C595, HMFG2 and SM3), tumor MUC1 was detected in 60/70 (86%) breast cancer specimens which reacted with at least one of these MAbs. High MUCI serum levels were detected in 14/67 (21%); IgG and IgM anti-MUC1 antibodies were found elevated in 32 and 14%, respectively, while IgG-MUC1-CIC-measured with C595 in 42% and IgM-MUC1-CIC in 54%; finally, SM3 was positive in 43 and 18%, respectively. Results of these studies demonstrate that in a group of breast cancer patients, MUC1 was detected both in tissue specimens as well as free in serum samples; furthermore, MUC1 can also circulate complexed with IgG and IgM antibodies; thus an accurate measurement should include free and complexed forms. On the other hand, immunohistochemical studies on breast cancer tissues may contribute to reveal different MUC1 glycoforms.
Asunto(s)
Adenocarcinoma/metabolismo , Biomarcadores de Tumor/metabolismo , Neoplasias de la Mama/metabolismo , Mucina-1/metabolismo , Neoplasias Ductales, Lobulillares y Medulares/metabolismo , Adenocarcinoma/sangre , Adulto , Anciano , Anciano de 80 o más Años , Complejo Antígeno-Anticuerpo/inmunología , Antígenos de Neoplasias/inmunología , Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/inmunología , Neoplasias de la Mama/sangre , Femenino , Humanos , Inmunoglobulina G/análisis , Inmunoglobulina M/análisis , Persona de Mediana Edad , Mucina-1/sangre , Mucina-1/inmunología , Neoplasias Ductales, Lobulillares y Medulares/sangre , Distribución TisularRESUMEN
OBJECTIVE: Gross cystic disease (GCD) is the most common benign breast pathology. Although breast cysts are not considered pre-malignant lesions, an increased risk of breast cancer has been reported for patients with type I cysts (Na(+)/K(+)<3). Furthermore, an augmented IGF-I/IGF-binding protein-3 (IGFBP-3) ratio has been described in breast cancer patients. The objective was to evaluate serum IGF-I and binding protein concentrations of type I and type II cyst patients as compared with healthy women. METHODS: Twenty-four patients with type I cysts, 17 with type II cysts and 25 healthy women were evaluated. Serum IGF-I, IGFBP-3 and IGFBP-1 concentrations were measured by IRMA. RESULTS: IGF-I concentrations were significantly higher in sera from patients with type I cysts than in patients with type II cysts. A highly significant decrease of IGFBP-3, the major IGFBP, was found in patients with type I cysts with respect to healthy women, whereas no significant difference was evident between the different cyst types. The IGF-I/IGFBP-3 ratio, an estimate of biologically active IGF-I, was very significantly higher in patients with type I cysts than in both type II patients and healthy women. IGFBP-1 levels were significantly lower in patients with type I than in controls and type II cysts. The IGF-I/IGFBP-1 ratio was significantly higher in patients with type I cysts than in type II bearers and healthy women. Estrogen levels correlated with IGF-I in patients and controls. CONCLUSIONS: The enhanced levels of IGF-I/IGFBP-3 found in patients with type I cysts could eventually be associated with the increased risk of breast cancer described for this group.